CytomX Therapeutics developed therapeutic candidates, including Antibody-Drug Conjugates (ADCs).
2 reports, 1 independent
Updated Aug 28
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CytomX Therapeutics developed therapeutic candidates, including Antibody-Drug Conjugates (ADCs).
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- CytomX Therapeutics announced clinical trial updates regarding its candidates, including CX-2051 for colorectal cancer and CX-801 for metastatic melanoma.Sub-event
CytomX Therapeutics announced the development of ADC therapeutic candidates.1 source
Keep exploring
The entities involved
-
CytomX Therapeutics (United States)
company in South San Francisco, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireCytomX Therapeutics to Present at Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the fiel
- GlobeNewswireCytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader